Don't Expect the New Anticoagulant Betrixaban to be Added to Your Formulary

March 2018

You'll hear buzz about betrixaban (Bevyxxa, beh-VYKE-sah), a new direct oral anticoagulant (DOAC) for extended VTE prophylaxis.

We know extending VTE prophylaxis after discharge is helpful for certain high-risk surgical patients...such as after hip or knee surgery. But the bleeding risk outweighs the benefit in most other patients.

Now betrixaban will be promoted for VTE prophylaxis in MEDICAL inpatients...and after discharge for up to 6 weeks total duration.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote